<DOC>
	<DOCNO>NCT03076905</DOCNO>
	<brief_summary>Open label evaluation single intravenous dose F901318 healthy male female subject pharmacokinetic safety tolerability evaluation .</brief_summary>
	<brief_title>Pharmacokinetics IV Formulation</brief_title>
	<detailed_description>Open label single intravenous dose , single group study . Eight subject ( ideally 4 male 4 female , minimum two female ) study . The IMP F901318 solution infusion ( 6mg/mL ) . The dose 4 mg/kg deliver fasted state ( 8 hour minimum ) intravenous infusion 2 hour . Each subject study approximately 6 week . Each subject reside Clinical Research Unit ( CRU ) Day -1 ( day dose ) Day 4 ( 72 hour post-dose ) . Blood sample pharmacokinetic evaluation obtain include 120 hour post dose . Safety tolerability also assess . Subjects return clinical unit 96 120 hour pharmacokinetic blood sampling . All subject return post-study visit 8 10 day dose study medication .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<criteria>1 . Subjects males female ethnic origin 18 55 year age weigh 50 100kg . 2 . Females child bear potential must establish reliable form contraception negative pregnancy test screen Day 1 3 . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation ( hepatic transaminase must within normal limit , congenital non haemolytic hyperbilirubinaemia acceptable ) 4 . Subjects give write informed consent participate study abide study restriction 1 . Female male subject , whose partner willing use appropriate contraception two reliable form contraception otherwise unable conceive child ( hysterectomy , oophorectomy , tubal ligation post menopausal ) . 2 . Subjects receive prescribed systemic topical medication within 14 day dose administration unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety 3 . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day dose administration ( exception vitamin/mineral supplement paracetamol ) unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>